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Polyoxazoline multivalently 
conjugated with indocyanine green 
for sensitive in vivo photoacoustic 
imaging of tumors
Kengo Kanazaki1,2,*, Kohei Sano1,3,*, Akira Makino1,4, Tsutomu Homma2, Masahiro Ono1 & 
Hideo Saji1
Photoacoustic imaging, which enables high-resolution imaging in deep tissues, has lately attracted 
considerable attention. For tumor imaging, photoacoustic probes have been proposed to enhance 
the photoacoustic effect to improve detection sensitivity. Here, we evaluated the feasibility of using 
a biocompatible hydrophilic polymer, polyoxazoline, conjugated with indocyanine green (ICG) as a 
tumor-targeted photoacoustic probe via enhanced permeability and retention effect. ICG molecules 
were multivalently conjugated to partially hydrolyzed polyoxazoline, thereby serving as highly 
sensitive photoacoustic probes. Interestingly, loading multiple ICG molecules to polyoxazoline 
significantly enhanced photoacoustic signal intensity under the same ICG concentration. In vivo 
biodistribution studies using tumor bearing mice demonstrated that 5% hydrolyzed polyoxazoline 
(50 kDa) conjugated with ICG (ICG/polyoxazoline = 7.8), P14-ICG7.8, showed relatively high tumor 
accumulation (9.4%ID/g), resulting in delivery of the highest dose of ICG among the probes tested. 
P14-ICG7.8 enabled clear visualization of the tumor regions by photoacoustic imaging 24 h after 
administration; the photoacoustic signal increased in proportion with the injected dose. In addition, 
the signal intensity in blood vessels in the photoacoustic images did not show much change, which was 
attributed to the high tumor-to-blood ratios of P14-ICG7.8. These results suggest that polyoxazoline-
ICG would serve as a robust probe for sensitive photoacoustic tumor imaging.
Optical technologies have greatly advanced in the past decades and have been applied for several medical imag-
ing techniques, including optical coherent tomography, fluorescence imaging, and photoacoustic (PA) imaging1. 
Among them, PA imaging, which detects ultrasound thermoelastically generated from the optical absorbers irra-
diated with pulsed laser, has emerged as an attractive modality due to sensitive and high resolution imaging at 
a depth of several centimeters in vivo2,3. Currently, various PA signal-enhancing contrast agents (PA probes), 
including metallic nanoparticles4,5 and fluorescence dyes6–8 have been reported to aid in the diagnosis of tumors. 
However, these probes still remain in pre-clinical and clinical trials and are not in clinical use.
Because of its biocompatibility9, PA probes labeled with indocyanine green (ICG), a US Food and Drug 
Administration (FDA)-approved near-infrared fluorescence dye, have been investigated10. In our previous stud-
ies, the feasibility of using proteins and polyethylene glycol (PEG) conjugated with ICG for tumor-targeted PA 
probes has been demonstrated11–13. PEG with large molecular weight (> 20 kDa) accumulated in the tumor via 
enhanced permeability and retention (EPR) effect14,15, and visualization of tumors was achieved in PA imag-
ing. However, the prolonged half-life of PEG in the blood lowered tumor-to-blood ratios, resulting in PA tumor 
images with low contrast (brightly enhanced blood vessels were seen). Furthermore, multiple ICG molecules 
could not be conjugated to PEG, because only the terminal of polymer could be used to conjugate (e.g. ICG/
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PEG = 1 in our previous study12). To overcome this problem, we selected polyoxazoline (POZ) as a novel carrier 
of PA signal emitters.
POZ, a hydrophilic polymer composed of N-acyl ethyleneimine with low toxicity in vitro and in vivo16,17, could 
be synthesized via living cationic ring-opening polymerization18,19. POZ could be characterized by rapid clear-
ance from the circulation20 and was utilized as a modulator of drug delivery carriers, including nanoparticles21,22 
and proteins23,24. However, no study has utilized POZ itself as a carrier of diagnostic probes. Therefore, in this 
study, the feasibility of using POZ labeled with ICG as a contrast agent for PA tumor imaging via the EPR effect 
was evaluated. Furthermore, we deduced that multiple ICG molecules could be conjugated with POZ through 
secondary amino groups introduced by hydrolyzing acyl groups of POZ25,26.
In this report, as shown in Fig. 1, we initially determined optimal molecular weight assuring tumor uptake 
via the EPR effect (Fig. 1A). Second, after partial hydrolysis of propionyl groups in POZ, the effect of hydrolysis 
ratio on tumor uptake was assessed (Fig. 1B). Third, we verified the relationship between the amount of ICG 
conjugated to POZ and tumor accumulation (Fig. 1C). Finally, we evaluated the feasibility of POZ multivalently 
conjugated with ICG (POZ-ICG) as a tumor-targeted probe for sensitive in vivo PA imaging.
Results
Optimization of Molecular Weight of POZ for Accumulation in Tumors via the EPR Effect. In 
order to determine the optimal molecular weight of POZ taken up by the tumor via the EPR effect, a series of POZ 
molecules conjugated with an ICG molecule were synthesized according to Supplementary Fig. S1A or S1B. The 
POZ polymer was synthesized via living cationic polymerization using microwave irradiation, and the molecular 
weight of the obtained POZ and number of ICG molecules conjugated to POZ are summarized in Table 1. The 
chemical purity of POZ-ICG was > 95%, as defined by size-exclusion chromatography (Supplementary Fig. S2).
POZ-ICG derivatives were administered into the colon 26 tumor-bearing mice, and the tumor uptake and 
blood clearance were investigated (Fig. 2). A high tumor uptake (11–13% injected dose (ID)/g) was observed 
when the molecular weight of POZ was 15.8 kDa and more, indicating that this range of molecular weight is 
preferable for efficient tumor uptake via the EPR effect. The half-life in the blood was prolonged as the molecu-
lar weight of POZ-ICG increased. However, tumor-to-blood (T/B) ratios at 24 h after injection were more than 
three when the molecular weight of POZ was less than 50 kDa, which was significantly higher than those of PEG 
conjugated with ICG (PEG-ICG) we have previously examined (T/B ratios; 1.2 and 0.7 at 24 h post-injection for 
PEG-ICG (20 kDa) and PEG-ICG (40 kDa), respectively). Therefore, the potential of POZ-ICG as a PA probe for 
tumor diagnosis was demonstrated. In order to ensure high level of tumor uptake and tumor-to-blood ratios, we 
selected POZ with molecular weight of 25 and 50 kDa for subsequent experiments.
Evaluation of Hydrolyzed POZ Conjugated with Multiple ICG Molecules. For the preparation of 
POZ conjugated with multiple ICG molecules, acyl groups of POZ were partially hydrolyzed by refluxing with 
hydrochloric acid (Supplementary Fig. S1B), resulting in introduction of secondary amino groups (2.5, 5, 10, 15, 
Figure 1. Drug design of POZ-ICG derivatives for sensitive PA tumor imaging in this study. We evaluated 
the influence of (A) molecular weight of POZ-ICG, (B) hydrolysis ratio in POZ-ICG, and (C) number of ICG 













Table 1.  Physicochemical properties of POZ-ICG derivatives having different molecular weights. 
aMolecular weight was determined by gel permeation chromatography (GPC) and expressed as weight-average 
molecular weight.
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and 20% hydrolysis ratio) (Supplementary Fig. S3). The pKa values and electric conductivity of each hydrolyzed 
POZ are summarized in Table 2. All of the POZ derivatives exhibited pKa values of approximately 10. Moreover, 
as the hydrolysis ratio of POZ increased, electric conductivity decreased due to consumption of protons.
Prior to conjugation of multiple ICG molecules into POZ, we evaluated the influence of POZ hydrolysis 
ratios (percentage of secondary amino groups per POZ polymer) on in vivo biodistribution. The accumulation 
of the POZ series labeled with ICG (ICG/POZ = 0.5–1.9) (Table 2) in the tumor was investigated using colon 26 
tumor-bearing mice. Independent of molecular weights of POZ (25 and 50 kDa), the tumor uptake was reduced 
as the hydrolysis ratios were increased (Fig. 3A–C). Moreover, increase in hydrolysis ratios was accompanied by 
rapid clearance of POZ from the blood, and the half-life of POZ in the blood was correlated with electrical con-
ductivity, as shown in Table 2.
Since high tumor uptake (more than 7%ID/g) was ensured in the hydrolysis ratios of 2.5–10% (Fig. 3C), con-
jugation of multiple ICG molecules was undertaken for POZ-ICG (25 and 50 kDa, 2.5–10% hydrolysis ratio), as 
shown in Table 3, and thereafter, in vivo biodistribution in colon 26 tumor-bearing mice was investigated. In the 
case of 2.5% hydrolysis ratio, as the number of ICG molecules conjugated to POZ increased, tumor accumulation 
Figure 2. In vivo fluorescent measurement of POZ-ICG derivatives with different molecular weights.  
(A) In vivo fluorescence imaging of tumor-bearing mice administered with POZ-ICG (left to right; P1-ICG1.1, 
P2-ICG1.1, P3-ICG0.9, P4-ICG0.7, P5-ICG0.8, P6-ICG1.0, and P7-ICG1.1). Dotted circles indicated the tumor 
regions. Scale bar units: photons/sec/cm2/steradian. (B) Tumor accumulation (%ID/g) (blue) and half-life in the 








Number of ICG molecules 
conjugated to POZ
Half-life in the 
bloodc (h)
P8-ICG1.5 25 2.5 10.1 3.9 1.5 4.9 ± 1.2
P9-ICG0.6 25 5 10.2 3.8 0.6 4.6 ± 0.6
P10-ICG0.6 25 10 10.2 3.4 0.6 3.8 ± 0.5
P11-ICG0.7 25 15 10.3 3.1 0.7 2.1 ± 0.4
P12-ICG1.9 25 20 10.2 2.9 1.9 1.1 ± 0.0
P13-ICG1.7 50 2.5 10.3 3.7 1.7 4.8 ± 1.2
P14-ICG0.5 50 5 10.2 3.4 0.5 4.5 ± 0.1
P15-ICG1.0 50 10 10.4 2.7 1.0 3.4 ± 0.4
P16-ICG1.1 50 15 10.3 2.4 1.1 2.0 ± 0.4
P17-ICG1.9 50 20 10.4 1.7 1.9 1.1 ± 0.2
Table 2.  Physicochemical properties and half-life in the blood of hydrolyzed POZ-ICG with different 
hydrolysis ratios. aMolecular weight was determined by gel permeation chromatography (GPC) and expressed 
as weight-average molecular weight. bpKa and electric conductivity were determined before ICG conjugation. 
cHalf-life of POZ-ICG in the blood was calculated based on probe concentration in blood collected from tumor-
bearing mice.
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slightly increased for both molecular weights (25 and 50 kDa) (Fig. 3D). However, a large amount of ICG could 
not be loaded due to limited reaction sites. Regarding 5% hydrolyzed POZ-ICG (50 kDa), tumor uptake was 
highly sustained when the number of ICG molecules introduced was up to 7.8. However, the introduction of 
excess ICG molecules severely compromised the delivery of POZ-ICG into tumor tissues. The other probes (5 and 
10% hydrolyzed POZ-ICG (25 kDa) and 10% hydrolyzed POZ-ICG (50 kDa)) demonstrated a decrease in tumor 
accumulation as the number of ICG increases. From the results of in vivo fluorescence imaging, POZ-ICG loaded 
with excess ICG molecules preferred hepatic uptake early post-injection (Fig. 3E). In order to elucidate this mech-
anism, the binding affinities of POZ-ICG derivatives (50 kDa, 5% hydrolyzed) to serum albumin were measured. 
When the number of ICG molecules loaded to POZ increased (1.9, 4.7, 7.8, and 10.3), the binding affinity to 
serum albumin (Kb values) also increased (3.0 ± 0.1, 3.5 ± 0.2, 8.7 ± 1.1, and 13.0 ± 0.4 M−1, respectively).
To investigate the probe accumulation in normal tissues, the fluorescence intensity in the liver and kidneys 
isolated from mice administered with POZ-ICG (50 kDa, hydrolysis ratio 5%, ICG/POZ = 1.9–10.3), which show 
high tumor accumulation, was measured. At 24 h after administration, while the fluorescence intensity in the liver 
was almost same among all of POZ-ICG, P14-ICG10.3 showed the highest intensity in the kidneys (Fig. 3F). The 
probe concentration in the blood at 24 h after administration decreased with increase in the number of conjugated 
ICG molecules (Supplementary Table S1). Therefore, tumor-to-blood ratios of all multivalently ICG-conjugated 
POZ were greater than 2.
In Vitro Fluorescence and PA Measurement. Owing to high tumor accumulation observed in the in vivo 
biodistribution study, we selected P14 (50 kDa, 5% hydrolysis ratio) conjugated with multiple ICG molecules (1.9, 
4.7, and 7.8) for the subsequent experiments. First, the fluorescence intensities of each compound and ICG were 
measured. The fluorescence intensity of POZ-ICG was decreased, accompanied by an increase in the number of 
ICG molecules loaded (Fig. 4). Subsequently, the PA signal intensity was measured. Interestingly, the PA signal 
Figure 3. Influence of POZ hydrolysis ratios and numbers of ICG molecules on in vivo biodistribution.  
(A) In vivo fluorescence imaging of tumor-bearing mice administered with POZ-ICG (25 kDa) (left to right; P8-
ICG1.5, P9-ICG0.6, P10-ICG0.6, P11-ICG0.7, and P12-ICG1.9, as shown in Table 2). (B) In vivo fluorescence 
imaging of tumor-bearing mice administered with POZ-ICG (50 kDa) (left to right; P13-ICG1.7, P14-ICG0.5, 
P15-ICG1.0, P16-ICG1.1 and P17-ICG1.9, as shown in Table 2). Dotted circles indicated tumor regions. Scale 
bar units: photons/sec/cm2/steradian. (C) Tumor accumulation of POZ-ICG (%ID/g) (Blue; 25 kDa, Red; 
50 kDa). (D) Tumor accumulation of POZ-ICG with molecular weight of 25 kDa (blue) and 50 kDa (red). 
Circles, squares, and triangles indicate hydrolysis ratios of 2.5, 5, and 10%, respectively. (E) In vivo fluorescence 
images of tumor bearing mice at 24 h (upper) and 1 h (lower) after administration of POZ-ICG. Left to right; 
P14-ICG1.9, P14-ICG4.7, P14-ICG7.8, P14-ICG10.3, and P10-ICG8.6. Dotted circles and white arrows indicate 
the tumor and liver regions, respectively. (F) Fluorescence intensity of liver and kidneys isolated from the mice 
at 24 h after administration of POZ-ICG (*P < 0.05).
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intensity of POZ-ICG was significantly increased with increase in the number of conjugated ICG molecules (39% 
increase for P14-ICG7.8) (Fig. 4) when compared under the same ICG concentration.
In Vivo Photoacoustic Imaging Study. Finally, we evaluated the feasibility of POZ-ICG as a 
tumor-targeted PA imaging probe. P14-ICG7.8 was investigated for further in vivo PA imaging studies because 
of the high tumor accumulation, high tumor-to-background ratio (Fig. 3), and high PA signal intensity (Fig. 4). 
In vivo PA imaging of tumor region (2 × 2 × 2 cm) at the mouse thigh was performed (Fig. 5A). Before probe 
injection, only blood vessels were observed (Fig. 5B, supplementary video S1). At 24 h after administration with 
P14-ICG7.8 (13 nmol or more), the tumor regions were clearly visualized and PA signal intensity in blood ves-
sels was hardly changed (Fig. 5C, supplementary video S2). The PA signal intensity in the tumor region was 
significantly higher than that in the non-tumor region when P14-ICG7.8 (52 nmol ICG) was administered 
(4.7 ± 2.5 × 105 vs 1.2 ± 0.6 × 105 (a.u.) for tumor vs non-tumor) (Fig. 5B,C). The increase in PA signal generated 
by P14-ICG7.8 in the tumor region had a good linearity relationship with the injected dose in the range of meas-
urement (124 ± 28, 181 ± 99, 279 ± 300, 731 ± 351%, and 830 ± 387% increase compared to pre-injection for 13, 
26, 52, 78, and 104 nmol ICG, respectively) (Fig. 5D). Furthermore, PA signal intensity was also in proportion 
with ICG concentration in isolated tumors (Fig. 5E).
Discussion
In this study, we synthesized POZ conjugated with multiple ICG molecules and optimized its molecular weight, 
hydrolysis ratio of acyl groups, and number of ICG loaded to POZ as a tumor-targeted PA imaging probe.
Based on tumor uptake and tumor-to-background ratios, optimal molecular weight was determined to be 








Number of ICG 
conjugated to POZ
P8-ICG0.7 25 2.5 1 0.7
P8-ICG1.5 25 2.5 3 1.5
P9-ICG0.6 25 5 2 0.6
P9-ICG2.6 25 5 10 2.6
P9-ICG5.4 25 5 20 5.4
P10-ICG0.6 25 10 2 0.6
P10-ICG4.4 25 10 10 4.4
P10-ICG8.6 25 10 20 8.6
P13-ICG1.7 50 2.5 3 1.7
P13-ICG2.8 50 2.5 10 2.8
P14-ICG0.5 50 5 2 0.5
P14-ICG1.9 50 5 10 1.9
P14-ICG4.7 50 5 20 4.7
P14-ICG7.8 50 5 40 7.8
P14-ICG10.3 50 5 300 10.3
P15-ICG1.0 50 10 2 1.0
P15-ICG3.6 50 10 10 3.6
P15-ICG9.0 50 10 20 9.0
P15-ICG10.7 50 10 40 10.7
Table 3.  Physicochemical properties of POZ conjugated with multiple ICG molecules. aMolecular weight 
was determined by gel permeation chromatography (GPC) and expressed as weight-average molecular weight.
Figure 4. Signal intensity ratio of POZ-ICG (P14-ICG1.9, P14-ICG4.7, and P14-ICG7.8) and ICG. Blue: 
fluorescence intensity ratio, red: PA signal intensity ratio. Data were normalized by the signal intensity of ICG.
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(Table 2). This result suggested that hydrolyzed POZ would be positively charged in vivo and that this charge 
could increase depending on the hydrolysis ratio. In in vivo biodistribution study, the half-life in the blood of 
POZ-ICG (hydrolysis ratio: 2.5–20%) decreased as electrical conductivity decreased as shown in Table 2, sug-
gesting that rapid clearance is related to the positive charge of POZ; especially high hepatic uptake of P12-ICG1.9 
and P17-ICG1.9 was noted early after injection by in vivo fluorescence imaging at 1 h after administration 
(Supplementary Fig. S4). This result was supported by previous reports wherein nanoparticles with positive 
charge showed shortened half-life in the blood27,28.
As we previously reported, pharmacokinetics of PEG-ICG were changed by interaction between ICG and 
serum albumin12. Therefore, we measured the binding affinity (Kb value) of POZ-ICG (50 kDa, 5% hydrolysis). Kb 
values increased as the number of ICG increased, suggesting that POZ-ICG with high Kb value accumulated in 
the liver not only via being albumin-probe macro-conjugates but also by orienting ICG to the liver. On the other 
hand, in some specific cases (i.e. 50 kDa, hydrolysis ratio 5%, ICG/POZ = 1.9–7.8), conjugation of ICG to POZ 
improved tumor uptake probably due to lowering hydrolysis ratios. Furthermore, the influence of hydrolysis ratio 
or number of ICG molecules loaded on tumor uptake was marked for low molecular weight of POZ (25 kDa).
In in vitro measurement, the fluorescence intensity of POZ-ICG was decreased as the number of ICG 
increased (Fig. 4), suggesting that fluorescence signal of ICG conjugated to POZ at high density was partially 
Figure 5. In vivo PA imaging of tumor-bearing mice administered P14-ICG7.8. Photographs of tumor-
bearing mice placed in the PA imaging device. (A) The square region indicates the measurement area.  
(B,C) PA images (view from the bottom) before (B) and at 24 h after (C) probe administration (Left to right: 
tumor regions injected with 13, 26, 52, 78, and 104 nmol ICG and non-tumor regions (thighs) injected with 
52 nmol ICG). Dotted circles and arrows indicated the tumor regions and blood vessels, respectively. Scale bar 
units: arbitrary unit. (D) Plot of PA signal intensity ratio (24 h/pre) vs. injected dose of P14-ICG7.8. (E) Plot of 
PA signal intensity ratio (24 h/pre) vs. P14-ICG7.8 concentration in isolated tumors.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:33798 | DOI: 10.1038/srep33798
quenched by intermolecular interaction, as reported previously29. On the other hand, the PA signal intensity was 
increased with increase in the number of ICG (Fig. 4), indicating that the fluorescence quenching energy of ICG 
was used to generate the PA signal. In addition, when ICG molecules were conjugated with POZ at high density, 
the thermal energy might be generated locally, which could improve its conversion efficiency to the acoustic 
signal30,31.
We have previously evaluated the feasibility of biocompatible and FDA-approved polymer (PEG and human 
serum albumin (HSA)) conjugated with ICG as PA probes11,12. POZ-ICG maintained high tumor accumula-
tion (9.4%ID/g at 24 h post-injection for P14-ICG7.8) even though large number of ICG molecules was loaded 
unlike ICG-conjugated HSA (HSA-ICG, ICG/HSA = 8.2) (2.1%ID/g at 24 h post-injection)11. Furthermore, POZ 
could be multivalently conjugated with ICG molecules compared with PEG-ICG (20 kDa, ICG/PEG = 1)12, and 
POZ-ICG showed high tumor-to-blood ratio without compromising tumor uptake. Although the tumor accu-
mulation of P14-ICG7.8 was slightly less (9.4 ± 0.6 and 14.9 ± 1.2%ID/g at 24 h post-injection for P14-ICG7.8 
and PEG-ICG, respectively), the PA signal intensity ratio (24 h post-injection/pre-injection) was comparable 
(8.3 ± 3.9 and 7.2 ± 2.1 for P14-ICG7.8 and PEG-ICG, respectively) when the same amount of ICG was injected. 
This was probably due to increase in PA signal per ICG molecules as shown in Fig. 4. These results demonstrated 
the benefits of POZ multivalently conjugated with ICG molecules for sensitive in vivo PA tumor imaging even 
if the lower dose of polymer was injected (≈ 10% compared with PEG). Furthermore, the tumor-to-blood ratios 
of P14-ICG7.8 were significantly higher than those of PEG-ICG (6.3 ± 1.0 and 1.2 ± 0.1 for P14-ICG7.8 and 
PEG-ICG, respectively). In fact, P14-ICG7.8 hardly changed the PA signal intensity in blood vessels while clearly 
visualizing tumor regions (Fig. 5B,C), thus, achieving high contrast tumor PA imaging. The biosafety of both 
ICG and POZ has been reported individually9,17. Furthermore, no noticeable side effect was observed in mice, 
suggesting low toxicity in the range of doses examined. Although the biosafety of POZ-ICG conjugate needs to be 
assessed in detail, the likelihood of smooth translation to the clinical study would be expected.
Conclusions
In this study, we elucidated (i) a potential of POZ-ICG for PA tumor imaging utilizing tumor accumulation via 
the EPR effect and (ii) loading of multiple ICG molecules achieved sensitive in vivo PA tumor imaging. Given 
tumor accumulation and tumor-to-background (blood) ratios, optimal molecular weight was determined to be 
25–50 kDa. Although the hydrolysis of propinyl groups in POZ partially compromised tumor accumulation due 
to increasing positive charge, 2.5–10% hydrolyzed POZ derivatives sustained their tumor uptake. Among contrast 
agents loaded with multiple ICG molecules, P14-ICG7.8 (5% hydrolyzed POZ (50 kDa) conjugated with ICG 
molecule of 7.8) exhibited high tumor uptake and background ratios. Furthermore, PA signals were significantly 
enhanced by loading multiple ICG molecules to POZ. Finally, P14-ICG7.8 clearly visualized the tumors with high 
contrast in the in vivo PA imaging study, suggesting the feasibility of POZ-ICG as a contrast agent for sensitive 
PA tumor imaging.
Methods
General. Proton nuclear magnetic resonance (1H NMR) spectra were obtained using a JEOL JNM-LM400 
with CDCl3 as a solvent and tetramethylsilane as an internal standard. Coupling constants are reported in hertz. 
Gel permeation chromatography (GPC) was performed with a LC-20AD Shimadzu pump and a Shimadzu RID-
10A refractive index detector equipped with a GPC column KD 804 (Showa Denko, Tokyo, Japan) with N,N-
dimethylformamide (DMF) as the mobile phase at a flow rate of 0.5 mL/min. Weight-average molecular weight 
was determined by a calibration curve calculated using PEG standards (Agilent Technologies, Santa Clara, CA, 
USA).
Materials. Methyl p-toluenesulfonate, ethylenediamine, and super dehydrated acetonitrile were purchased 
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 2-Ethyl-2-oxazoline was purchased from Tokyo 
Chemical Industry Co., Ltd. (Tokyo, Japan). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(WSC) was purchased from Dojindo Molecular Technologies, Inc. (Kumamoto, Japan). 4-Dimethylaminopyridine 
(DMAP) and 2 mol/l-hydrochloric acid were purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Poly(2-ethyl-
2-oxazoline) (molecular weight: 25, 50, and 200 kDa) was purchased from Sigma-Aldrich Japan (Tokyo, Japan). 
1H-Benz[e]indolium, 2-[7-[3-(5-carboxypentyl)-1,3-dihydro-1,1-dimethyl-2H-benz[e]indol-2-ylidene]-
1,3,5-heptatrien-1-yl]-1,1-dimethyl-3-(4-sulfobutyl), inner salt (ICCA) was synthesized according to previously 
reported method32. All other chemicals of highest purity available were used.
Cell Culture and Animal Model. A mouse rectal cancer cell line, colon 26, was purchased from Riken Bio 
Resource Center (Ibaraki, Japan). The cells were maintained according to previous report11.
Animal studies were conducted in accordance with the institutional guidelines of Kyoto University and the 
experimental procedures were approved by the Kyoto University Animal Care Committee. Tumor-bearing mice 
were prepared as reported previously11. Briefly, colon 26 (1 × 106 cells) suspended in 50 μ L PBS were inoculated 
subcutaneously in the shoulders or thighs of the mice. Experiments with tumor-bearing mice were performed 7 
days after inoculation.
Preparation of POZ-ICG. POZ (molecular weight: 7.7–31 kDa) was synthesized via a microwave irradia-
tion method as previously reported18,19. Briefly, methyl p-toluenesulfonate (5 mg, 1 eq.) and 2-ethyl-2-oxazoline 
(1.1 g, 400 eq.) were dissolved in super dehydrated acetonitrile (0.5–3 mL) in a capped reaction tube and stirred 
for 14 min at 140 °C by microwave irradiation using the Discover system (CEM Co., Matthews, NC, USA). 
Subsequently, ethylenediamine (16 mg, 10 eq.) was added to the reaction solution and stirred for 7 min at 140 °C 
via microwave irradiation. After solvent evaporation, the resulting mixture was dissolved in 2 mL methanol and 
dialyzed against methanol with pre-treated regenerated cellulose (RC) membrane Spectra/Por® 7 dialysis tubing 
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(molecular weight cut-off: 3.5 kDa) (Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA) for purifica-
tion. The resulting polymer was analyzed by 1H NMR and GPC. 1H NMR (CDCl3): δ [ppm] = 3.3–3.6 (br, 4nH, 
NCH2CH2N), 2.2–2.5 (br, 2nH, C= OCH2), 1.0–1.2 (br, 3nH, CH3).
POZ (7.7–31 kDa) (50–200 mg, 1 eq.) was stirred with ICCA (10 mg, 2 eq.), WSC (2.5 mg, 2 eq.), and 
DMAP (1.6 mg, 2 eq.) in chloroform (2 mL) at r.t. for 24 h with shielding from light. After solvent evapora-
tion, the resulting mixture was dissolved in methanol (2 mL) and dialyzed against methanol as mentioned 
above to remove unconjugated ICCA. The concentration of ICG was determined by measuring the absorp-
tion at 795 nm in the presence of 5% SDS with a UV-Vis NIR system (UV-1800, Shimadzu Co., Kyoto, 
Japan). To determine the chemical purity, the purified POZ-ICG (100 pmol ICG) was separated by PD-10 
column.
Preparation of Hydrolyzed POZ Conjugated with Multiple ICG Molecules. For preparation of POZ 
loaded with multiple ICG molecules, poly(2-ethyl-2-oxazoline) (molecular weight: 25, 50, 200 kDa) was hydro-
lyzed to introduce secondary amine groups according to a previous report26. Briefly, poly(2-ethyl-2-oxazoline) 
in distilled and deionized water (250 mg, 25 mg/mL) was mixed with hydrochloric acid (2 M, 0.1–0.8 mL) and 
refluxed in an oil bath for 24 h. After neutralization, the resulting solution was freeze-dried. Finally, after fil-
tration of the resulting mixture dissolved in chloroform using celite, partly hydrolyzed POZ was obtained. 1H 
NMR (CDCl3): δ [ppm] = 3.3–3.6 (br, 4nH, CH2N(C= O)CH2), 2.6–2.9 (br, 4nH, CH2NHCH2), 2.2–2.5 (br, 2nH, 
C= OCH2), 1.0–1.2 (br, 3nH, CH3).
The hydrolysis ratio of hydrolyzed POZ was determined by 1H NMR and electric conductivity measure-
ment. The electric conductivity of hydrolyzed POZ in 0.01 M hydrochloric acid (60 μ M) was measured by 
LAQUAtwin COND (Horiba, Ltd., Kyoto, Japan). The pKa value of each hydrolyzed POZ was determined 
using acid-base titration as previously reported33. Briefly, hydrolyzed POZ (0.6 μ mol amino group) was dis-
solved in ddH2O (1 mL) and mixed with aqueous sodium hydroxide (0.01 M, 60 μ L) to deprotonize all the 
amino groups. Neutralizing titration using 0.001 M hydrochloric acid was performed with a 9618S-10D pH 
meter (Horiba, Ltd.).
Subsequently, hydrolyzed POZ was conjugated with ICCA. POZ (25, 50 and 200 kDa) (10 mg, 1 eq.) was 
stirred with ICCA (1–300 eq.), WSC (1–300 eq.), and DMAP (1–150 eq.) in chloroform (2 mL) at r.t. for 24 h 
with shielding from light. The resulting solution was purified as mentioned above, and the purity of hydrolyzed 
POZ-ICG was determined by size exclusion chromatography.
The binding affinities of POZ-ICG to albumin were measured using previously reported procedures12. Briefly, 
each POZ-ICG (0–100 μ M) was incubated with bovine serum albumin (BSA) (4 μ M) for 30 min for equilibra-
tion. The fluorescence intensity of tryptophan in BSA was measured using a spectrofluorophotometer (RF-6000, 
Shimadzu Co., ex/em 279/342 nm). The binding affinity of each compound to BSA was calculated from the Hill 
equation.
Fluorescence Measurement of POZ-ICG. The accumulation of POZ-ICG in the tumor was measured 
as reported previously11,12. Briefly, POZ-ICG (13 nmol ICG in 100 μ L PBS) was intravenously injected into 
the colon 26 tumor-bearing nude mice (n = 3). At 1 and 24 h after administration of POZ-ICG, whole-body 
fluorescence images were acquired using the IVIS Imaging System 200 (ex: 745 nm, em: 840 nm, exposure 
time: 1 sec). At 24 h after administration, the tumors were excised and homogenized by adding 1% triton-X aque-
ous solution. After centrifugation, the supernatant (2 μ L) was mixed with DMSO (18 μ L) to extract POZ-ICG, 
and the fluorescence intensity was measured. In the same way, the mouse blood (2 μ L) was collected at 5, 15, and 
30 min, and 1, 3, 6, and 24 h after administration, then the blood was mixed with a 1% triton-X aqueous solution 
(9 μ L) and DMSO (9 μ L), and the fluorescence intensity was measured. The concentration of each POZ-ICG 
(%ID/g) in the tumor and blood was calculated using a standard curve prepared from each POZ-ICG diluted 
with tumor homogenate and blood, respectively. Tumor-to-blood ratio was calculated as a ratio of concentration 
of POZ-ICG (%ID/g) in the tumor and blood. The half-life of POZ-ICG in the blood was calculated by GraphPad 
Prism software (GraphPad Prism software, Inc. La Jolla, CA, USA). At 24 h after administration, the liver and kid-
neys were resected and the fluorescence intensity was measured using the IVIS Imaging System 200 (ex: 745 nm, 
em: 840 nm, exposure time: 1 sec).
In Vitro Fluorescence and PA Measurement. Fluorescence intensity of POZ-ICG in 50 mg/mL BSA 
aqueous solution (15 μ M ICG) was measured (ex: 785 nm, em: 815 nm) with an Infinite® 200 PRO plate reader 
(Tecan Japan Co., Ltd., Kanagawa, Japan).
The photoacoustic signal measurement system was assembled as previously reported12. The PA signal intensity 
of POZ-ICG in 50 mg/mL BSA aqueous solution (15 μ M ICG) was normalized by both the pulsed light intensity 
and the sample concentration.
In Vivo PA Imaging. In vivo PA imaging was performed with an Endra Life Sciences Nexus 128 instrument 
(Endra Inc., Ann Arbor, MI, USA) as previously reported11,12. POZ-ICG (13, 26, 52, 78, and 104 nmol ICG in 
100 μ L PBS) was intravenously injected into the colon 26 tumor-bearing mice (n = 4). PA images of tumor region 
and non-tumor region (thigh) were acquired (120 angles, 20 pulses/angle, 797 nm) before injection and at 24 h 
after injection. The tumor was positioned at the center of the PA imaging region to ensure that the same regions 
could be imaged before and after probe administration. The 2D and 3D PA images were described via OsiriX soft-
ware and PA signal intensity was calculated from the value of data points in volume rendering images normalized 
with irradiated laser intensity.
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Statistical Analysis. Statistical significance among groups was identified using the two-tailed Student’s t-test. 
Data are presented as the mean ± standard deviation. P values of less than 0.05 were considered statistically significant.
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